Recently we received the report from the Data Safety Monitoring Committee. The overall message was that STEPCARE trial shall continue as planned. There is adequate separation for all interventions, the data is complete, and the recruitment is steady. The next interim will be when 1250 participants have passed 30-day follow-up, which likely will be in February/March 2025.